12-102843777-G-T
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PM3_StrongPP4_ModeratePM2PVS1
This summary comes from the ClinGen Evidence Repository: PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: gnomAD MAF 0.00017; PP4_Moderate: Detected in PKU patients (PMID:25894915); PM3_Strong: in trans with p.W326X (Pathogenic), and IVS4-1G>A (Pathogenic). (PMID:25894915). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate, PM3_Strong). LINK:https://erepo.genome.network/evrepo/ui/classification/CA273107/MONDO:0009861/006
Frequency
Consequence
NM_000277.3 stop_gained, splice_region
Scores
Clinical Significance
Conservation
Publications
- phenylketonuriaInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P, ClinGen, Myriad Women’s Health
- classic phenylketonuriaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- maternal phenylketonuriaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- mild hyperphenylalaninemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- mild phenylketonuriaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuriaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 16 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000277.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PAH | NM_000277.3 | MANE Select | c.1068C>A | p.Tyr356* | stop_gained splice_region | Exon 11 of 13 | NP_000268.1 | ||
| PAH | NM_001354304.2 | c.1068C>A | p.Tyr356* | stop_gained splice_region | Exon 12 of 14 | NP_001341233.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PAH | ENST00000553106.6 | TSL:1 MANE Select | c.1068C>A | p.Tyr356* | stop_gained splice_region | Exon 11 of 13 | ENSP00000448059.1 | ||
| PAH | ENST00000307000.7 | TSL:5 | c.1053C>A | p.Tyr351* | stop_gained splice_region | Exon 12 of 14 | ENSP00000303500.2 | ||
| PAH | ENST00000635477.1 | TSL:5 | c.171C>A | p.Tyr57* | stop_gained splice_region | Exon 4 of 6 | ENSP00000489230.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.0000120 AC: 3AN: 251004 AF XY: 0.0000221 show subpopulations
GnomAD4 exome AF: 0.00000342 AC: 5AN: 1461382Hom.: 0 Cov.: 33 AF XY: 0.00000413 AC XY: 3AN XY: 727022 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Phenylketonuria Pathogenic:8
Null variant in a gene where loss of function (LOF) is a known mechanism of disease.;For recessive disorders, detected in trans with a pathogenic variant.;Patient's phenotype or family history is highly specific for a disease with a single genetic etiology.
This sequence change creates a premature translational stop signal (p.Tyr356*) in the PAH gene. RNA analysis indicates that this premature translational stop signal induces altered splicing and may result in an absent or altered protein product. This variant is present in population databases (rs62516095, gnomAD 0.02%). This premature translational stop signal has been observed in individuals with PAH deficiency-related disease (PMID: 7915167, 27264808). ClinVar contains an entry for this variant (Variation ID: 92729). Studies have shown that this premature translational stop signal results in altered splicing, and produces a non-functional protein and/or introduces a premature termination codon (PMID: 10471838). For these reasons, this variant has been classified as Pathogenic.
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.
PVS1+PM2+PM3_VS+PP4_M
Variant summary: PAH c.1068C>A (p.Tyr356X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 1.2e-05 in 245780 control chromosomes (gnomAD). c.1068C>A has been reported in the literature in multiple individuals affected with Phenylalanine Hydroxylase Deficiency (Phenylketonuria) (Tao_2015, Eiken_1996). These data indicate that the variant is very likely to be associated with disease. Three ClinVar submissions from clinical diagnostic laboratories and reputable databases (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: gnomAD MAF 0.00017; PP4_Moderate: Detected in PKU patients (PMID:25894915); PM3_Strong: in trans with p.W326X (Pathogenic), and IVS4-1G>A (Pathogenic). (PMID:25894915). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate, PM3_Strong).
not provided Pathogenic:2Other:1
The Y356X nonsense variant in the PAH gene has been reported as a pathogenic variant in the PAHConsortium database. The Y356X variant has been previously reported in individuals withphenylketonuria (PKU) (Liang et al., 2014; Liu et al., 2015; Chen et al., 2015; Jeannesson-Thivisol etal., 2015). Functional analysis found that Y356X is associated with significantly reduced enzymeactivity compared to wild type (Zurfluh et al., 2008). It has been reported as non-responsive totetrahydrobiopterin (BH4) therapy (Zurfluh et al., 2008; Jeannesson-Thivisol et al., 2015). TheY356X variant is predicted to cause loss of normal protein function either through protein truncationor nonsense-mediated mRNA decay.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at